Clinical efficacy of combination of oxaliplatin and vascular intervention in treatment of advanced cervical cancer and related prognostic factors

被引：2
作者：
Huang, Xinlong [1 ]
Yang, Haiyan [2 ]
Su, Zhenqing [1 ]
Wang, Junsong [1 ]
Zhang, Jianxun [1 ]
Zhang, Xinqin [2 ]
机构：
[1] First Peoples Hosp Wenling, Dept Vasc Tumor Intervent, Wenling 317500, Peoples R China
[2] First Peoples Hosp Wenling, Dept Gynecol, Wenling 317500, Peoples R China
来源：
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH | 2022年 / 21卷 / 03期
关键词：
Oxaliplatin; Vascular intervention; Advanced cervical cancer; Prognosis; CELLS;
D O I：
10.4314/tjpr.v21i3.26
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Purpose: To investigate the therapeutic effect of combination of oxaliplatin and vascular intervention in patients with advanced cervical cancer (ACC), and its influence on the prognosis of patients. Methods: One hundred ACC patients were selected and equally assigned to control (oxaliplatin) and combination or study (oxaliplatin plus vascular intervention) groups. The patients in control group received oxaliplatin, while those in study group were treated with oxaliplatin combined with vascular intervention. Clinical efficacy, levels of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor-2 (VEGFR-2), fibroblast growth factor-2 (FGF-2), BFGF and platelet-derived growth factor (PDGF) before and after therapy, and survival rate at 3, 6, 12 and 18 months after therapy were determined compared between the two groups. The prognostic factors were analyzed with logistic factor analysis. Results: The clinical efficacy and survival rate at 3, 6, 12 and 18 months after therapy in the combination group were higher when compared with those of the control group (p < 0.05). After therapy, the levels of VEGF, VEGFR-2, FGF-2, BFGF and PDGF were lower in the combination group than in control group. Age, short-term efficacy and basic diseases were identified as the influencing factors for the prognosis of patients with advanced cervical cancer (p < 0.05). Conclusion: The combination of oxaliplatin and vascular intervention significantly improved clinical treatment efficacy and survival rate in ACC patients. Age, short-term efficacy and basic diseases affected the prognosis of patients.
引用
收藏
页码：643 / 648
页数：6
相关论文
共 50 条
[41]   Apoptosis-related Prognostic Factors in Advanced Colorectal Cancer Determined Using Tissue Microarrays [J].
Ozaki, Kosuke ;
Sasaki, Kazuhito ;
Abe, Hiroyuki ;
Nozawa, Hiroaki ;
Murono, Koji ;
Emoto, Shigenobu ;
Ushiku, Tetsuo ;
Ishihara, Soichiro .
ANTICANCER RESEARCH, 2023, 43 (09) :3935-3942
[42]   Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy Combined with Intracavitary Posterior Radiotherapy for the Treatment of Medium-Term and Advanced Cervical Cancer: Efficacy, Safety and Prognostic Factors [J].
Yu, Kewen ;
Zhou, Liping .
FRONTIERS IN SURGERY, 2022, 9
[43]   Analysis of the treatment efficacy and prognostic factors of PD-1/PD-L1 inhibitors for advanced gastric or gastroesophageal junction cancer: a multicenter, retrospective clinical study [J].
Yang, Yuanyuan ;
Wang, Zhe ;
Xin, Dao ;
Guan, Lulu ;
Yue, Bingtong ;
Zhang, Qifan ;
Wang, Feng .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[44]   Novel strategies in HPV-16-related cervical cancer treatment: An in vitro study of combined siRNA-E5 with oxaliplatin and ifosfamide chemotherapy [J].
Rasizadeh, Reyhaneh ;
Aghbash, Parisa Shiri ;
Mokhtarzadeh, Ahad ;
Poortahmasebi, Vahdat ;
Oskouee, Mahin Ahangar ;
Nahand, Javid Sadri ;
Amini, Mohammad ;
Mahdavi, Seyedeh Zahra Bahojb ;
Yari, Amir Hossein ;
Baghi, Hossein Bannazadeh .
GENE, 2025, 932
[45]   Observation of Curative Efficacy and Prognosis Following Combination Chemotherapy with Celecoxib in the Treatment of Advanced Colorectal Cancer [J].
Jin, C-H ;
Wang, A-H ;
Chen, J-M ;
Li, R-X ;
Liu, X-M ;
Wang, G-P ;
Xing, L-Q .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2011, 39 (06) :2129-2140
[46]   Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer Treatment outcome outside clinical trials [J].
Winkler, J. ;
Zipp, L. ;
Knoblich, J. ;
Zimmermann, F. .
STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (05) :377-382
[47]   Prognostic prediction of oxidative stress related hematological biomarkers in locally advanced cervical cancer patients undergoing chemoradiotherapy [J].
Wu, Gang ;
Gu, Mengxuan ;
Zhu, Jiahao ;
Gu, Ruike ;
Yang, Bo ;
Ji, Shengjun ;
Zhao, Yutian ;
Gu, Ke .
BIOMARKERS, 2024, 29 (05) :255-264
[48]   Efficacy and prognostic factors of PD-1 inhibitors combined with apatinib in advanced diffuse gastric cancer [J].
Chen, Beibei ;
Zhao, Huichen ;
Hu, Huihui ;
Huang, Jinxi ;
Liu, Yingjun ;
Lv, Huifang ;
Xu, Weifeng ;
Wang, Jianzheng ;
Nie, Caiyun ;
Zhao, Jing ;
He, Yunduan ;
Wang, Saiqi ;
Wang, Yuhang ;
Chen, Xiaobing .
NEOPLASMA, 2025, 72 (1-2) :128-136
[49]   Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer [J].
Qi, Q. ;
Geng, Y. ;
Sun, M. ;
Wang, P. ;
Chen, Z. .
PANCREATOLOGY, 2015, 15 (02) :145-150
[50]   The clinical outcome and prognostic factors after multi-visceral resection for advanced colon cancer [J].
Yun, S. H. ;
Yun, H. R. ;
Lee, W. S. ;
Cho, Y. B. ;
Lee, W. Y. ;
Chun, H. K. .
EJSO, 2009, 35 (07) :721-727
12345